Now the question for Celgene is whether it can expand this franchise even further and substantially boost revenue before Revlimid loses patent protection in 2022. Celgene has launched numerous studies of Revlimid in other types of blood cancer (lymphoma and leukemia) in the hopes of adding those incremental billions of revenue dollars.